Bicyclic SHP2 Inhibitors for N-SH2 Allosteric Targeting
Solution Overview
Problem
Current therapies lack effective small molecules to inhibit the activity of SHP2, a non-receptor protein tyrosine phosphatase implicated in various diseases such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, and cancers of the breast and lung.
Innovation Solution
Development of bicyclic compounds that inhibit the activity of SHP2 by targeting specific domains within the protein, including Formula I, Formula II, Formula III, and Formula IV, which are capable of modulating the catalytic activity of SHP2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then existing treatment options are available, but effective small molecules to inhibit SHP2 activity are lacking
Solution Approach 1:
The patent segments the SHP2 protein into functional domains (N-SH2 domain, C-SH2 domain, and PTP domain) and designs compounds that specifically target the N-SH2 domain. This segmentation allows for selective inhibition of SHP2 activity while preserving other cellular functions, resolving the contradiction by providing reliable SHP2 inhibition through domain-specific targeting.
Solution Approach 2:
The patent introduces bicyclic compounds as intermediary molecules that mediate between the N-SH2 domain of SHP2 and the catalytic site. These compounds act as allosteric inhibitors by binding to the N-SH2 domain and inducing conformational changes that inhibit catalytic activity, thereby providing effective SHP2 inhibition where previous therapies failed.
2Object-affected harmful factors
If SHP2 activity is inhibited, then diseases associated with aberrant SHP2 function can be treated, but the mechanism of inhibition must be precisely targeted
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (bicyclic core with particular substituent patterns) that are optimized for binding to the N-SH2 domain. The compounds contain specific functional groups (such as heterocyclic rings and aromatic moieties) that interact with key residues in the N-SH2 domain, ensuring precise local targeting while achieving broad therapeutic effects against SHP2-driven diseases.
Solution Approach 2:
The patent employs asymmetry in the molecular design of SHP2 inhibitors, creating non-symmetric bicyclic structures with specific spatial arrangements of functional groups. This asymmetric design allows for selective binding to the asymmetric N-SH2 domain interface, enhancing targeting precision while effectively inhibiting aberrant SHP2 function in various diseases.
Data Source
AI summary
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.